ClearPoint Neuro (NASDAQ:CLPT) Director Sells $65,900.55 in Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Timothy Richards sold 5,415 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $12.17, for a total value of $65,900.55. Following the completion of the sale, the director directly owned 87,198 shares of the company’s stock, valued at approximately $1,061,199.66. This represents a 5.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

ClearPoint Neuro Stock Up 7.7%

Shares of ClearPoint Neuro stock opened at $14.32 on Friday. The company has a quick ratio of 4.88, a current ratio of 5.79 and a debt-to-equity ratio of 2.63. The firm has a market cap of $429.46 million, a P/E ratio of -14.18 and a beta of 1.31. ClearPoint Neuro, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $30.10. The business has a 50-day moving average price of $10.98 and a 200 day moving average price of $12.48.

ClearPoint Neuro (NASDAQ:CLPT) last issued its earnings results on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The company had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million. On average, sell-side analysts forecast that ClearPoint Neuro, Inc. will post -1.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CLPT has been the subject of a number of research reports. B. Riley Financial lifted their target price on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Monday, April 20th. Finally, Stifel Nicolaus initiated coverage on ClearPoint Neuro in a research note on Friday, May 8th. They issued a “buy” rating and a $16.00 target price for the company. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $18.00.

Hedge Funds Weigh In On ClearPoint Neuro

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new position in ClearPoint Neuro in the 4th quarter valued at about $25,000. BNP Paribas Financial Markets grew its position in ClearPoint Neuro by 2,435.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after buying an additional 2,143 shares in the last quarter. Legal & General Group Plc bought a new position in ClearPoint Neuro in the 2nd quarter valued at about $35,000. Huntington National Bank bought a new position in ClearPoint Neuro in the 3rd quarter valued at about $44,000. Finally, Russell Investments Group Ltd. grew its position in ClearPoint Neuro by 1,079.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after buying an additional 2,158 shares in the last quarter. Institutional investors own 30.08% of the company’s stock.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.